News

Luther Turmelle April 1, 2020 Updated: April 1, 2020 4:54 p.m. Doug Manion, CEO of Kleo Pharmaceuticals in New Haven, right, meets with city officials and others in this file photo.  Photo: … [Read more...] about New Haven Biotech Company Joins Race To Develop Coronavirus Drug

Kleo’s First Non-Oncology Application of Its Antibody Recruiting Molecule (ARM™) to Be Tested in Combination with GCLC’s NK Cells as a Potential COVID-19 Therapeutic   New Haven, CT, … [Read more...] about Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy

Former Board Chairman Dr. Tom Lynch, New President and Director at Fred Hutchinson Cancer Research Center, to Remain a Consultant New Haven, CT, February 14, 2020 – Kleo Pharmaceuticals, Inc., an … [Read more...] about Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board

We have noticed the emergence of an interesting trend that is popping up in the emerging biopharmaceutical industry: platform technologies, which differ from one company to the next. In Kleo’s case, … [Read more...] about Platform Technologies Emerge in Biopharma

New Haven, CT, December 18, 2019/PRNewswire/-- Kleo Pharmaceuticals, Inc., an immuno-oncology company developing next-generation, fully synthetic bispecific compounds designed to emulate or enhance … [Read more...] about Kleo Pharmaceuticals to Present at Biotech Showcase 2020